Diabetic Neuropathy-Pipeline Review, H1 2015

Diabetic Neuropathy-Pipeline Review, H1 2015

  • Products Id :- GMDHC6713IDB
  • |
  • Pages: 114
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Diabetic Neuropathy-Pipeline Review, H1 2015


Global Markets Direct's, 'Diabetic Neuropathy-Pipeline Review, H1 2015', provides an overview of the Diabetic Neuropathy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diabetic Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Diabetic Neuropathy and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Diabetic Neuropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Diabetic Neuropathy pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathy

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Diabetic Neuropathy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Diabetic Neuropathy Overview 9

Therapeutics Development 10

Pipeline Products for Diabetic Neuropathy-Overview 10

Pipeline Products for Diabetic Neuropathy-Comparative Analysis 11

Diabetic Neuropathy-Therapeutics under Development by Companies 12

Diabetic Neuropathy-Therapeutics under Investigation by Universities/Institutes 14

Diabetic Neuropathy-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Diabetic Neuropathy-Products under Development by Companies 18

Diabetic Neuropathy-Products under Investigation by Universities/Institutes 20

Diabetic Neuropathy-Companies Involved in Therapeutics Development 21

Acorda Therapeutics, Inc. 21

Araim Pharmaceuticals Inc. 22

Astellas Pharma Inc. 23

Cebix Incorporated 24

Eli Lilly and Company 25

Glucox Biotech AB 26

Longevity Biotech, Inc 27

Lpath, Inc. 28

Neuralstem, Inc. 29

Omeros Corporation 30

Pfizer Inc. 31

R-Tech Ueno, Ltd. 32

Spinifex Pharmaceuticals Pty Limited 33

Sumitomo Dainippon Pharma Co., Ltd. 34

Virobay Inc. 35

ViroMed Co., Ltd. 36

Diabetic Neuropathy-Therapeutics Assessment 37

Assessment by Monotherapy Products 37

Assessment by Target 38

Assessment by Mechanism of Action 40

Assessment by Route of Administration 42

Assessment by Molecule Type 44

Drug Profiles 46

Antimunocel-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

ARA-290-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

ASP-8477-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

BBI-21007-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Biologic for Diabetic Nephropathy-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

BNV-222-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

capsaicin-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

CBX-129801-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Cyndacel-M-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

Drug for Peripheral Neuropathic Pain and Diabetic Peripheral Neuropathy-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

EMA-401-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

ketoprofen-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Lpathomab-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

NRD-135SE1-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

NSI-566-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

OMS-721-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

PF-05089771-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

ranirestat-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

Recombinant Protein to Antagonize VEGFR-2 for Oncology and Metabolic Disorders-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

RTU-1096-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

Small Molecule to Inhibit NOX-4 for Diabetic Neuropathy-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

Small Molecules for Diabetic Neuropathy-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

Synthetic Peptides for Central Nervous System Disorders and Diabetic Neuropathy-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

VBY-285-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

VM-202-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

Diabetic Neuropathy-Recent Pipeline Updates 84

Diabetic Neuropathy-Dormant Projects 100

Diabetic Neuropathy-Discontinued Products 104

Diabetic Neuropathy-Product Development Milestones 106

Featured News & Press Releases 106

Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition 106

Sep 23, 2013: Lpath Awarded NIH SBIR Grant for Lpathomab 107

Jun 09, 2012: Cebix's Ersatta Demonstrates Encouraging Results In Phase I Study Of Diabetic Peripheral Neuropathy 108

Sep 12, 2011: Spinifex Pharmaceuticals Presents New Data On EMA401 In Model Of Diabetic Neuropathy At 21st Annual NEURODIAB Meeting 109

Sep 07, 2011: Cebix To Chair Symposium On C-Peptide And Pathophysiology Of Diabetes At EASD Annual Meeting 109

May 11, 2011: Dainippon Sumitomo Pharma Announces Results Of Phase II Clinical Trial For Ranirestat For Diabetic Complications 110

Mar 18, 2011: ViroMed Enrolls Final Patient For US VM202-DPN Phase I/II Clinical Trial 111

Mar 04, 2009: ViroMed Receives Approval from US FDA for Phase I/II Trial for Diabetic Neuropathy 111

Sep 29, 2005: Dainippon And Eisai Signs Licensing Agreement For A Potential New Treatment For Diabetic Neuropathy 111

Appendix 113

Methodology 113

Coverage 113

Secondary Research 113

Primary Research 113

Expert Panel Validation 113

Contact Us 113

Disclaimer 114

List of Tables

Number of Products under Development for Diabetic Neuropathy, H1 2015 10

Number of Products under Development for Diabetic Neuropathy-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 13

Number of Products under Investigation by Universities/Institutes, H1 2015 14

Comparative Analysis by Late Stage Development, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Development, H1 2015 17

Products under Development by Companies, H1 2015 18

Products under Development by Companies, H1 2015 (Contd..1) 19

Products under Investigation by Universities/Institutes, H1 2015 20

Diabetic Neuropathy-Pipeline by Acorda Therapeutics, Inc., H1 2015 21

Diabetic Neuropathy-Pipeline by Araim Pharmaceuticals Inc., H1 2015 22

Diabetic Neuropathy-Pipeline by Astellas Pharma Inc., H1 2015 23

Diabetic Neuropathy-Pipeline by Cebix Incorporated, H1 2015 24

Diabetic Neuropathy-Pipeline by Eli Lilly and Company, H1 2015 25

Diabetic Neuropathy-Pipeline by Glucox Biotech AB, H1 2015 26

Diabetic Neuropathy-Pipeline by Longevity Biotech, Inc, H1 2015 27

Diabetic Neuropathy-Pipeline by Lpath, Inc., H1 2015 28

Diabetic Neuropathy-Pipeline by Neuralstem, Inc., H1 2015 29

Diabetic Neuropathy-Pipeline by Omeros Corporation, H1 2015 30

Diabetic Neuropathy-Pipeline by Pfizer Inc., H1 2015 31

Diabetic Neuropathy-Pipeline by R-Tech Ueno, Ltd., H1 2015 32

Diabetic Neuropathy-Pipeline by Spinifex Pharmaceuticals Pty Limited, H1 2015 33

Diabetic Neuropathy-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 34

Diabetic Neuropathy-Pipeline by Virobay Inc., H1 2015 35

Diabetic Neuropathy-Pipeline by ViroMed Co., Ltd., H1 2015 36

Assessment by Monotherapy Products, H1 2015 37

Number of Products by Stage and Target, H1 2015 39

Number of Products by Stage and Mechanism of Action, H1 2015 41

Number of Products by Stage and Route of Administration, H1 2015 43

Number of Products by Stage and Molecule Type, H1 2015 45

Diabetic Neuropathy Therapeutics-Recent Pipeline Updates, H1 2015 84

Diabetic Neuropathy-Dormant Projects, H1 2015 100

Diabetic Neuropathy-Dormant Projects (Contd..1), H1 2015 101

Diabetic Neuropathy-Dormant Projects (Contd..2), H1 2015 102

Diabetic Neuropathy-Dormant Projects (Contd..3), H1 2015 103

Diabetic Neuropathy-Discontinued Products, H1 2015 104

Diabetic Neuropathy-Discontinued Products (Contd..1), H1 2015 105

List of Figures

Number of Products under Development for Diabetic Neuropathy, H1 2015 10

Number of Products under Development for Diabetic Neuropathy-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Comparative Analysis by Late Stage Development, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Products, H1 2015 17

Assessment by Monotherapy Products, H1 2015 37

Number of Products by Stage and Top 10 Targets, H1 2015 38

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 40

Number of Products by Top 10 Routes of Administration, H1 2015 42

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 43

Number of Products by Top 10 Molecule Types, H1 2015 44

Number of Products by Stage and Top 10 Molecule Types, H1 2015 45

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Acorda Therapeutics, Inc.

Araim Pharmaceuticals Inc.

Astellas Pharma Inc.

Cebix Incorporated

Eli Lilly and Company

Glucox Biotech AB

Longevity Biotech, Inc

Lpath, Inc.

Neuralstem, Inc.

Omeros Corporation

Pfizer Inc.

R-Tech Ueno, Ltd.

Spinifex Pharmaceuticals Pty Limited

Sumitomo Dainippon Pharma Co., Ltd.

Virobay Inc.

ViroMed Co., Ltd.

Diabetic Neuropathy Therapeutic Products under Development, Key Players in Diabetic Neuropathy Therapeutics, Diabetic Neuropathy Pipeline Overview, Diabetic Neuropathy Pipeline, Diabetic Neuropathy Pipeline Assessment

select a license

Single User License
USD 2000 INR 134900
Site License
USD 4000 INR 269800
Corporate User License
USD 6000 INR 404700



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com